Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 1682 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study
Claire Owen¹, Gene Ngian², Kathleen Elford², Owen Moore³, Mandy Nikpour³, Wendy Stevens³, Susanna Proudman⁴, Janet Roddy⁵, Jane Zochling⁶, Catherine Hill⁷, Peter Nash⁸, Allan Sturgess⁹ and Joanne Sahhar², ¹Rheumatology, Monash Health, Melbourne, Australia, ²Monash Health, Melbourne, Australia, ³St Vincent's Hospital, Melbourne, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia, ⁵Royal Perth Hospital, Perth, Australia, ⁶Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia, ⁷Queen Elizabeth Hospital, Adelaide, Australia, ⁸Sunshine Coast Rheumatology, Maroochydore, Australia, ⁹The St George Hospital, Sydney, Australia
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is common and when progressive, associated with significant morbidity and mortality. Cyclophosphamide is frequently used as first line…
Abstract Number: 1677 • 2014 ACR/ARHP Annual Meeting
Association of Gastrointestinal Symptoms with Immunosuppressant Use in the Prospective Registry of Early Systemic Sclerosis Cohort
Tracy M. Frech¹, Maureen Murtaugh², Ami A. Shah³, Jessica K. Gordon⁴, Victoria K. Shanmugam⁵, Robyn T. Domsic⁶, Monique Hinchcliff⁷, Faye N. Hant⁸, Shervin Assassi⁹, Virginia D. Steen¹⁰ and Dinesh Khanna¹¹, ¹Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ²Internal Medicine-Division of Epidemiology, University of Utah School of Medicine, SLC, UT, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, The George Washington University, Washington, DC, ⁶Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Dept of Medicine, Medical Univ of South Carolina, Charleston, SC, ⁹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹⁰Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ¹¹University of Michigan Health System, Ann Arbor, MI
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) is a multicenter incident cohort study of patients with early diffuse cutaneous systemic sclerosis (dcSSc; <…
Abstract Number: 877 • 2014 ACR/ARHP Annual Meeting
Sildenafil Attenuates the Fibrotic Phenotype in Scleroderma Skin Fibroblasts
Tomoaki Higuchi¹, Yasushi Kawaguchi¹, Kae Takagi¹, Akiko Tochimoto¹, Yuko Ota², Yasuhiro Katsumata¹, Takahisa Gono¹, Masanori Hanaoka¹, Yuko Okamoto¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²10-22 Kawada-Cha Shinjuku-Ku, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Systemic sclerosis (SSc) is a connective tissue disease characterized by inflammation, vasculopathy and fibrosis. Tissue fibrosis directly contributes to mortality or quality of life.…
Abstract Number: 772 • 2014 ACR/ARHP Annual Meeting
RNA-Seq and Mir-Seq Analysis of SSc Skin Across Intrinsic Gene Expression Subsets Shows Differential Expression of Non-Coding RNAs Regulating SSc Gene Expression
Zhenghui Li¹, Eleni Marmarelis², Kun Qu³, Lionel Brooks⁴, Patricia Pioli⁴, Howard Chang³, Robert Lafyatis⁵ and Michael Whitfield⁴, ¹Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, ³Stanford University School of Medicine, Stanford, CA, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH, ⁵Arthritis Center, Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease with a heterogenous and complex phenotype. Previously, our lab has identified four gene expression subsets (fibroproliferative,…
Abstract Number: 770 • 2014 ACR/ARHP Annual Meeting
Detection of Proteins in Lung Tissues of Patients with Systemic Sclerosis Using Tissue Microarrays
Frank Schneider¹ and Carol A. Feghali-Bostwick², ¹Pathology, University of Pittsburgh, Pittsburghh, PA, ²Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Research on systemic sclerosis (SSc)-associated interstitial lung disease (ILD) has been hindered by the paucity of lung tissues, as SSc patients with lung involvement…
Abstract Number: 765 • 2014 ACR/ARHP Annual Meeting
Gene-Gene Interaction of IRF5 and BLK Polymorphisms in US and Spanish Cohorts of Systemic Sclerosis (SSc)
Pravitt Gourh¹, Yoonhee Kim², Sandeep K. Agarwal³, Filemon K. Tan⁴, Shervin Assassi⁴, Javier Martin⁵, Frank C. Arnett⁴ and Maureen D Mayes⁴, ¹NIAMS-Rheumatology, National Institutes of Health, Bethesda, MD, ²NIH, Bethesda, MD, ³Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁵Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose Systemic sclerosis (SSc) is a complex autoimmune disease and several genetic loci increasing SSc susceptibility have been identified with small to modest effect sizes.…
Abstract Number: 760 • 2014 ACR/ARHP Annual Meeting
Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis
Kristina E.N. Clark¹, Henry Lopez², Xu Shiwen¹, Bahja Ahmed Abdi¹, George Martin³, Korsa Khan⁴, David J. Abraham¹, Christopher P. Denton⁵ and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Murigenics, Vallejo, CA, ³Aero Dap, Vallejo, CA, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose Clinical diversity in systemic sclerosis (SSc) suggests complex multifaceted pathogenesis involving interplay of growth factors or cytokines within the lesional microenvironment. We analysed dermal…
Abstract Number: 2998 • 2014 ACR/ARHP Annual Meeting
Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study
Thomas Frauenfelder¹, Anna Winklehner¹, Thi Dan Linh Nguyen¹, Rucsandra Dobrota^2,3, Stephan Baumüller¹, Britta Maurer² and Oliver Distler², ¹Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high…
Abstract Number: 2917 • 2013 ACR/ARHP Annual Meeting
Mortality, Recurrence, and Hospital Course of Patients With Systemic Sclerosis Related Acute Intestinal Pseudo-Obstruction
Chris T. Derk¹, Nora Sandorfi², Shivani Purohit³ and Christopher Mecoli⁴, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, Thomas Jefferson Univ Med Coll, Philadelphia, PA, ³Rheumatology Division, Department of Medicine, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Acute intestinal pseudo-obstruction is a rare gastrointestinal manifestation of SSc with little data existing as to the demographics, clinical course, outcomes and mortality of…
Abstract Number: 2739 • 2013 ACR/ARHP Annual Meeting
Immunochip Analysis Identifies New Susceptibility Loci For Systemic Sclerosis: Implications For Pathogenesis
Maureen D. Mayes for the US Scleroderma GWAS Group¹, Lara Bossini-Castillo for the Spanish Scleroderma Group², Olga Gorlova³, Jose Ezequiel Martin⁴, Xiaodong Zhou¹, Wei Chen⁵, Shervin Assassi¹, Jun Ying⁵, John D. Reveille¹, Peter K. Gregersen⁶, Annette T. Lee⁷, Maria Teruel⁸, Francisco David Carmona⁴, Bobby P.C. Koeleman⁹, Matthew A. Brown and the Immunochip Consortium¹⁰, Christopher P. Denton¹¹, Murray Baron for the Canadian Scleroderma Research Group¹², Jasper Broen¹³, T.R.D.J. Radstake¹³ and Javier Martin⁴, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ³Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ⁵Department of Epidemiology, UT M.D. Anderson Cancer Center, Houston, TX, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁸Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ⁹Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁰Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ¹¹Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ¹²Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ¹³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose : The purpose of this study was to identify SSc risk loci shared with other autoimmune diseases on the Immunochip and to fine-map previously…
Abstract Number: 2609 • 2013 ACR/ARHP Annual Meeting
Dutch Translation and Validation Of The University of California, Los Angeles scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0
Jessica Meijs¹, Daisy Pors¹, Theodora P.M. Vliet Vlieland², Tom W.J. Huizinga¹ and Annemie J.M. Schuerwegh¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 90% of the patients with systemic sclerosis (SSc) and leads to a decrease in health-related quality of…
Abstract Number: 2582 • 2013 ACR/ARHP Annual Meeting
Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort
Virginia D. Steen¹ and Robyn T. Domsic², ¹Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ²Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Trials of therapy in pulmonary hypertension(PH) have generally excluded patients with significant interstitial lung disease, but many patients with systemic sclerosis(SSc) and PH have…
Abstract Number: 2576 • 2013 ACR/ARHP Annual Meeting
Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
Adrienne M. Roos¹, Christopher Pasarikovski¹, Amie T. Kron¹, John T. Granton², Peter Lee³, John Thenganatt⁴ and Sindhu R. Johnson⁵, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ⁴Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Divisions of Respirology and Critical Care Medicine, Toronto, ON, Canada, ⁵Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Epoprostenol has been demonstrated to improve hemodynamics, functional class, and six-minute walk distance (6MWD) in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH…
Abstract Number: 2577 • 2013 ACR/ARHP Annual Meeting
Sex Disparities In Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients
Christopher Pasarikovski¹, John T. Granton², Peter Lee³, Adrienne M. Roos¹, Amie T. Kron¹, Cathy Chau⁴ and Sindhu R. Johnson⁵, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ⁴Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Medicine, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and idiopathic PAH (IPAH) are conditions with poor survival. There is evidence to suggest that sex…
Abstract Number: 1810 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort
Hebah Alhajeri¹, Marie Hudson², Marvin J. Fritzler³, Janet E. Pope⁴, Canadian Scleroderma Research Group -⁵ and Murray Baron⁶, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴St Joseph Health Care, London, ON, Canada, ⁵Jewish General Hospital, Montreal, QC, Canada, ⁶Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: New classification criteria for systemic sclerosis (SSc) have recently been developed. In this study, we aimed to assess the sensitivity of this classification in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].